The evolving role of targeted drugs in the treatment of Hodgkin lymphoma

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

(2017) Robert Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP escalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group

(2017) Peter Borchmann et al.   LANCET ONCOLOGY

Hodgkin Lymphoma

(2017) Richard T. Hoppe et al.   Journal of the National Comprehensive Cancer Network

Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma

(2016) A. Kumar et al.   BLOOD

Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials

(2016) B. Boll et al.   BLOOD

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

(2016) R. Chen et al.   BLOOD

Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy

(2016) Carmen Martínez et al.   BRITISH JOURNAL OF HAEMATOLOGY

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

(2016) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

(2016) Margaretha G.M. Roemer et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

(2016) Anas Younes et al.   LANCET ONCOLOGY

Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation

(2016) Bastian von Tresckow et al.   LEUKEMIA & LYMPHOMA

Current and future immunotherapeutic approaches in Hodgkin lymphoma

(2016) Paul J. Bröckelmann et al.   LEUKEMIA & LYMPHOMA

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

(2016) Douglas B. Johnson et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

(2015) A. Rothe et al.   BLOOD

Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older

(2015) Andres Forero-Torres et al.   BLOOD

Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group

(2015) Dennis A. Eichenauer et al.   JOURNAL OF CLINICAL ONCOLOGY

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Craig H Moskowitz et al.   LANCET

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study

(2015) Alison J Moskowitz et al.   LANCET ONCOLOGY

Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group

(2015) D A Eichenauer et al.   LEUKEMIA

Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma

(2015) Michael Schaapveld et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2014) D. A. Eichenauer et al.   ANNALS OF ONCOLOGY

Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event

(2014) M. D. Gandhi et al.   BLOOD

Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group

(2014) D. A. Eichenauer et al.   BLOOD

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

(2014) A. K. Gopal et al.   BLOOD

Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project

(2014) Kenneth R. Carson et al.   CANCER

Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte–Predominant Hodgkin Lymphoma

(2014) Ranjana H. Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation†

(2013) C. Martínez et al.   ANNALS OF ONCOLOGY

Treatment-Related Mortality in Patients With Advanced-Stage Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group

(2013) Diana Wongso et al.   JOURNAL OF CLINICAL ONCOLOGY

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study

(2013) Anas Younes et al.   LANCET ONCOLOGY

Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant

(2013) Sally Arai et al.   LEUKEMIA & LYMPHOMA

Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplant

(2013) Bastian von Tresckow et al.   LEUKEMIA & LYMPHOMA

Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma

(2012) R. Chen et al.   BLOOD

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

(2012) A. Younes et al.   BLOOD

Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma

(2012) Y. L. Kasamon et al.   BLOOD

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

Gonadal Function and Fertility in Survivors After Hodgkin Lymphoma Treatment Within the German Hodgkin Study Group HD13 to HD15 Trials

(2012) Karolin Behringer et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group

(2011) D. A. Eichenauer et al.   BLOOD

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma

(2011) T. A. Fehniger et al.   BLOOD

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial

(2011) Anas Younes et al.   LANCET ONCOLOGY

A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

(2010) Patrick B. Johnston et al.   AMERICAN JOURNAL OF HEMATOLOGY

Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma

(2010) Andreas Josting et al.   JOURNAL OF CLINICAL ONCOLOGY

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma

(2009) Andres Forero-Torres et al.   BRITISH JOURNAL OF HAEMATOLOGY